NIPTE-FDA Collaborative Case Study On Model-based Design Space Development Across Scales & with Stability Considerations Preliminary Design Space 1.

Slides:



Advertisements
Similar presentations
High Shear Granulation Scale-Up Mohsen Sadatrezaei Pharm.D.
Advertisements

Right the First Time Program Office
National Institute for Pharmaceutical Technology and Education (NIPTE) Interim Risk Assessment Report.
Methods of tablet manufacturing
Satish Mallya January 20-22, |1 | 3-1. Assessing Batch Records Satish Mallya Quality Workshop, Copenhagen May 18-21,2014 May 18-21,2014.
1 Implementation of Quality by Design (QbD): Status, Challenges and Next Steps Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS,
Manufacturing Process
Wet Granulation Scale-up Experiments. Scale-up Approach with Dimensional Numbers 2 The effect of process parameter (i.e., impeller speed, liquid addition.
BY: Chris Tremblay.  Piece of equipment used to remove moisture from a wet solid by bringing the moisture into a gaseous state.  A drying medium (usually.
II. Properties of Fluids. Contents 1. Definition of Fluids 2. Continuum Hypothesis 3. Density and Compressibility 4. Viscosity 5. Surface Tension 6. Vaporization.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Implementation of ICH Q8, Q9, Q10.
Quality by Design (QbD) in Product Development
Drying in the Pharmaceutical Industry1 DIT- Msc Pharmaceutical and Chemical Processes Technologies 28 th April 2009 Sara Baeza.
Risk Assessment in QbD David R. González Barreto 1 QbD Risk Assessment in QbD Introduction and Few Tools David R. González Barreto.
Process Analytical Technologies Subcommittee Product and Process Development: An Industry Perspective David Rudd PhD Process Technology GlaxoSmithKline.
World Health Organization
6th CPH assessment training workshop May 2014
Learnings from Pre-approval Joint Inspection of a GSK QbD Product with US-FDA & EMA and the application of Continuous Verification 17 May 2011, Beijing,
Quality By Design and Dissolution PhRMA 10/25/05
Application of the principles of QbD in vaccines production Andrea Pranti.
4. Phase Relations (Das, Chapter 3) Sections: All except 3.6
Annex I: Methods & Tools prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9 QUALITY.
FDA Regulatory Perspective on Continuous Manufacturing
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Implementation of ICH Q8, Q9, Q10.
Slide 1 May 2008 Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Mumbai, India Date: May 2008 QUALITY BY DESIGN.
Carl A. Anderson, Ph.D. James K. Drennen, III, Ph. D.
Quality by Design Application of Pharmaceutical QbD for Enhancement of the Solubility and Dissolution of a Class II BCS Drug using Polymeric Surfactants.
DEVELOPMENT OF QUALITY BY DESIGN (QBD) GUIDANCE ELEMENTS ON DESIGN SPACE SPECIFICATIONS ACROSS SCALES WITH STABILITY CONSIDERATIONS Fluid Bed Drying Small.
DRYING Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D
Module 1, Part 3: Process validation Slide 1 of 22 © WHO – EDM – 12/2001 Validation Part 3: Process validation Supplementary Training Modules on Good Manufacturing.
Prepared by: Marcia C. Belcher Construction Engineering Technology.
1 Specific Gravity. 2 Specific Gravity Gs 3 Phase Material.
1-7.The ICH Q8 “Minimal Approach” to Pharmaceutical Development
CHEE 4401 DRYING u we are primarily concerned with drying wet porous solids (granules) u important in ensuring proper moisture content  low enough to.
Linking Drug Stability to Manufacturing Risk Assessment Approaches L. E. Kirsch Stability team leader.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Implementation of ICH Q8, Q9, Q10.
BioTx Pharmaceutical Sciences Movement within the design space with a robust control strategy Jon Coffman, Ph.D. Principal Engineer III BioTherapeutic.
DEVELOPMENT OF QUALITY BY DESIGN (QBD) GUIDANCE ELEMENTS ON DESIGN SPACE SPECIFICATIONS ACROSS SCALES WITH STABILITY CONSIDERATIONS Scale-up Experimentation.
Critical Material Properties for Pharmaceutical Dosage Forms - Industry Perspective Tony Hlinak Abbott Laboratories North Chicago, IL.
Small molecules Liquids – Solvent composition – Reactions – HME Dry Powder – Blending – Dry Granulation – Dry milling Wet solids – API Crystallization.
Workshop Session 3 Questions 1 How would a control strategy look different in a traditional submission vs a QbD submission? How would parameters that are.
Math – What is a Function? 1. 2 input output function.
NIPTE-FDA Collaborative Case Study On Model-based Design Space Development Across Scales & with Stability Considerations Design Space Integration 1.
Satish Mallya January 20-22, |1 | 2-3. Pharmaceutical Development Satish Mallya Quality Workshop, Copenhagen May 18-21, 2014 May 18-21,2014.
ENERGY CONVERSION MME 9617A Eric Savory Lecture 10 – Analyzing a complete plant: Energy conversion cycles Department.
General Aspects of Quality assessment of multisource interchangeable medicines Rutendo Kuwana Technical Officer, WHO, Geneva Training workshop: Assessment.
1 Views expressed in this presentation are my own, and do not necessarily reflect official FDA opinions/policy Views expressed in this presentation are.
Linking Drug Stability to Manufacturing Risk Assessment Approaches L. E. Kirsch Stability team leader.
GRANULATION DR. MOHAMMAD KHALID ANWER Assistant Professor 2/25/20161 COLLEGE OF PHARMACY, PRINCE SATTAM BIN ABDULAZIZ UNIVERSITY.
Tablet Granulation. Introduction  Granulation is the process in which primary powder particles are made to adhere to form larger, multi particle entities.
开发报批美国 FDA 的仿制药 与相关问题探讨 上海复星普适医药科技有限公司何平. 内容提要 开发仿制药的重要性和机遇 开发仿制药的重要性和机遇 开发仿制药的挑战 开发仿制药的挑战 申报仿制药的分类 申报仿制药的分类 仿制药研发团队 仿制药研发团队 仿制药的研发过程 仿制药的研发过程 QbD 在制剂开发中怎么体现.
QbD Technologies: Workshop for Risks Management Incorporating Risk Management for Technology Transfer.
TABLET GRANULATION TECHNIQUES.
Methods of tablet manufacturing
QbD Technologies: Workshop for Risks Management Incorporating Risk Management for Technology Transfer.
Integration of Excipients into the Design of Experiments for Pharmaceutical Product and Design Space Development Chris Moreton, Ph.D. FinnBrit Consulting.
Faculty of Pharmacy and Medical Sciences Al-Ahliyya Amman University
TYPES OF DATA Prof. Dr. Hamit ACEMOĞLU. The aim By the end of this lecture, students will be avare of types of data.
A custom designed sequential workflow
A QbD Approach to Process Development: Defining Critical Quality Attributes and Evaluating Criticality Across Scales Carl A. Anderson, Duquesne University.
Quality by design (Qbd)
5. WEIGHT VOLUME RELATIONSHIPS
IPSA (Industrial Problem Solving Ability )
Dr Dehghan M. H Professor in Pharmaceutics,
Wet Granulation Small Scale Experiments
QUALITY BY DESIGN Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Mumbai, India Date: May 2008.
Notes Over 2.1 Function {- 3, - 1, 1, 2 } { 0, 2, 5 }
Michael I. Sadowski, Chris Grant, Tim S. Fell  Trends in Biotechnology 
Implementation of Quality by Design (QbD): Status, Challenges and Next Steps Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS, CDER.
Quality by Design.
Presentation transcript:

NIPTE-FDA Collaborative Case Study On Model-based Design Space Development Across Scales & with Stability Considerations Preliminary Design Space 1

QbD process 2 Define Target Product Profile (TPP) Derive Quality Attributes from TPP Propose Manufacturing Process Risk Analysis (FMEA) Risk Evaluation (Risk-based Classification) Propose Parameters to Investigate (e.g., by DOE) PROCESS DESIGN SPACE

Basic Processing Sequence 3 RA Results

CPPs

Design Space Definition 5 For each unit op establish functional relationships of CPP and CQA of input materials with CQA of output materials –e.g. disintegration time ~ compression force and hydrophobicity Establish interactions between unit ops –e.g. hardness ~ PSD and compression force Establish design space boundaries by propagating backwards limits imposed on final product CQAs

Design Space Definition 6 courtesy: Dr. Steef. Boerrighter, Purdue University

Preliminary Design Space 7 Considered –Degradation NMT 0.4 mole % lactam –Hardness NLT 3 kP –Weight variation 90 % - 110% % RSD NMT 6% DS definition for 15 CPPs Interactions were established for some CPPs –one or more slides included to describe those interactions There were no significant interactions for few CPPs –ranges for those are shown in slide 18

Tablet Hardness ~ Intermediate CQA 8 Compression Force Bulk density 0.52 kg/m 3 Bulk density 0.46 kg/m 3 Median PS

Tablet Hardness ~ Intermediate CQA 9 PAT application: Real time measurement of bulk density and particle size

Tablet Hardness ~ Tabletting CPP 10 Min Punch Gap Press speed tab/hr Press speed tab/hr Comp. Height

Preliminary Tabletting Design Space 11

12 Blending 12 Significant increase in STS at extreme conditions

Tablet Hardness ~ Drying CPP 13 EEF End Moisture Target = 0.5% End Moisture Target = 1% Comp. Force

L 0, D 0 ~ Drying CPP 14 D 0, crystal damage L 0, in-process lactam X – Wet Massing Time Y – Water Content

Preliminary Drying Design Space 15

Tablet Hardness ~ Granulation CPP 16 WMT=60s Water Content WMT=0s Comp. Force

Preliminary Granulation Design Space 17

Preliminary Design Space 18 Granulation –Impeller speed 500 RPM Fr 1.20 –Critical Fr determined for 4 L Gral at 250 RPM = 0.30 Drying –End Product Target Temperature 25°C – 30°C Blending –15 – 25 RPM –60% – 80% fill ratio –# of rotations:

Summary 19 Risk Assessment helps to identify CPP Preliminary Design Space is defined by backward propagation Some PPs identified by RA are not critical in the explored experimental domain Preliminary Design Space is constructed for: –Wet granulation –Fluidized bed drying –Blending –Tabletting Some interactions between unit ops were considered –Tabletting and intermediate CQA –Fluidized bed drying and tabletting –Wet granulation and tabletting